Standard & Poor’s will make changes to several U.S. indexes next week, including the S&P MidCap 400, the S&P SmallCap 600, and the widely used S&P 500. The changes, which reflect the effects of acquisitions and market cap chang…
At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off…
With King in its fold, Pfizer — which makes Lyrica and Celebrex — believes it can build an industry-leading portfolio of pain relievers. Among King’s most appealing entrants in that market is the new Embeda, designed to preve…